Concerning the harm-benefit ratio of escitalopram for pediatric generalized anxiety disorder. A critical viewpoint on the evidence and approval process

International Journal of Risk and Safety in Medicine · Published 2026-05-28 · DOI 10.1177/09246479261456063

Free full text

Authors (5)

Martin Plöderl, Mark Horowitz, Florian Naudet, John Warren, Joanna Moncrieff

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Plöderl, M., Horowitz, M., Naudet, F., et al. (2026). Concerning the harm-benefit ratio of escitalopram for pediatric generalized anxiety disorder. A critical viewpoint on the evidence and approval process. International Journal of Risk and Safety in Medicine. https://doi.org/10.1177/09246479261456063

Related articles

• Impact of proton pump inhibitors on clinical outcomes and adverse drug reactions in antiplatelet therapy: A prospective study from an Indian hospital · International Journal of Risk and Safety in Medicine · 2026 · Same journal
• Integrating Cochrane methodology into medical education: Experience and outcomes · International Journal of Risk and Safety in Medicine · 2026 · Same journal
• Pharmacoepidemiological analysis of antiplatelet drug consumption in outpatient practice · International Journal of Risk and Safety in Medicine · 2025 · Same journal
• Author’s response: Rates of successful conceptions according to COVID-19 vaccination status: Data from the Czech Republic · International Journal of Risk and Safety in Medicine · 2025 · Same journal
• Follow-up on test referrals and results: Whose responsibility is it? · International Journal of Risk and Safety in Medicine · 2025 · Same journal
• Prevalence and predictors of self-medication among adults in Mbeya Urban, Tanzania · International Journal of Risk and Safety in Medicine · 2026 · Same journal
• Post-SSRI Sexual Dysfunction (PSSD): A comprehensive review of epidemiology, pathophysiology, and clinical management · International Journal of Risk and Safety in Medicine · 2026 · Same journal
• Flurbiprofen-induced upper respiratory and ocular adverse effects in a patient having non-cardiac chest pain · International Journal of Risk and Safety in Medicine · 2025 · Same journal
• Feeding tube safety: National guidance is unsafe and must change · International Journal of Risk and Safety in Medicine · 2026 · Same journal
• Use of nootropics in Alzheimer’s disease: An analysis of regulatory positions and drug policies in the countries of the Commonwealth of Independent States · International Journal of Risk and Safety in Medicine · 2025 · Same journal